Core Insights - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics, which are custom-built protein drugs aimed at addressing medical challenges that other drug modalities cannot effectively tackle [3] Group 1: Company Overview - Molecular Partners AG is pioneering the design and development of DARPin therapeutics, with a primary focus on oncology [3] - The company has various programs in different stages of pre-clinical and clinical development [3] - Founded in 2004, Molecular Partners has offices in Zurich, Switzerland, and Concord, Massachusetts, USA [3] Group 2: Upcoming Presentation - The CEO, Patrick Amstutz, will present the company's latest developments and outlook for 2025 at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2025 [2] - The presentation will take place from 10:30 AM to 11:10 AM PT at the Westin St. Francis in San Francisco, CA [2] - A webcast of the presentation will be available on the Molecular Partners website [2]
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference